LYEL vs. DNTH, CRMD, QURE, ETNB, CGEM, LENZ, PHAR, ABUS, IMNM, and EOLS
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Dianthus Therapeutics (DNTH), CorMedix (CRMD), uniQure (QURE), 89bio (ETNB), Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), Pharming Group (PHAR), Arbutus Biopharma (ABUS), Immunome (IMNM), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs.
Lyell Immunopharma (NASDAQ:LYEL) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
Dianthus Therapeutics received 9 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 95.83% of users gave Dianthus Therapeutics an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.
Lyell Immunopharma has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.
Dianthus Therapeutics has higher revenue and earnings than Lyell Immunopharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Dianthus Therapeutics has a net margin of -1,250.32% compared to Lyell Immunopharma's net margin of -323,792.09%. Dianthus Therapeutics' return on equity of -21.68% beat Lyell Immunopharma's return on equity.
Lyell Immunopharma presently has a consensus target price of $1.00, suggesting a potential upside of 73.76%. Dianthus Therapeutics has a consensus target price of $46.43, suggesting a potential upside of 132.14%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Lyell Immunopharma.
In the previous week, Dianthus Therapeutics had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Dianthus Therapeutics and 2 mentions for Lyell Immunopharma. Dianthus Therapeutics' average media sentiment score of 0.80 beat Lyell Immunopharma's score of 0.54 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Dianthus Therapeutics beats Lyell Immunopharma on 14 of the 19 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 1/18/2025 by MarketBeat.com Staff
Free LYEL Stock Alerts